Serum Institute of India (SII) CEO Adar Poonawalla on Monday said he hopes to resolve the issues that Covishield-vaccinated Indians who are planning to travel to Europe are facing.

In a tweet, Poonawalla said, "I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries."

The SII manufactures the Oxford University's anti-COVID-19 vaccine AstraZeneca in India named Covishield.

The European Union (EU) is planning to roll out from July 1 a new plan under which a "digital COVID certificate" will be introduced for travelling.

The certificate will be proof that the holder is vaccinated against the virus.

The EU's medical regulatory body has listed four anti-COVID-19 vaccines including AstraZeneca. However, Covishield does not feature in the list.

At present, only two vaccines, Covishield and the indigenous Covaxin, have been rolled out in India.(SAM)